The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 726-734

  Ohashi, Naro ^a   Uematsu, Toshihiko ^b   Nagashima, Satoru ^b   Kanamaru, Mitsutaka ^b   Togawa, Akashi ^a   Hishida, Akira ^a   Uchida, Eiji ^c   Akizawa, Tadao ^d   Koshikawa, Shozo ^e  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shitoro Clinic   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Calcimimetic agent; Calcium sensing receptors; End stage renal disease; KRN 1493; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM ION; CINACALCET; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; MALE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 2942511328     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02088.x     Document Type: Article

References (31)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56(Suppl 73): S14-9.
2. Massry SG, Coburn JW, Popovtzer MM, Shinaberger JH, Maxwell MH, Kleeman CR. Secondary hyperparathyroidism in chronic renal failure. Arch Intern Med 1969; 124: 431-41.
3. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14: 219-31.
4. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-92.
5. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-20.
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17.
7. Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA. Who gets renal bone disease before beginning dialysis? Br Med J 1985; 290: 271-5.
8. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-42.
9. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-9.
10. Salusky IB, Kuizon BD, Belin TR. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54: 907-14.
11. 2 (paricalcitol) safely and effectively reduces the levels of PTH in patients with hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32.
12. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-201.
13. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
14. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29: 641-9.
15. Cunningham J. What is the optimal regimen for vitamin D? Kidney Int 1999; 56(Suppl 73): S59-S64.
16. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 25: 1226-37.
17. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-81.
18. Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF. Allosteric activation of the calcium receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53: 1083-8.
19. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-5.
20. Nemeth EF. Calcium receptors as novel drug targets. In Principles in Bone Biology, eds Bilezikian JP, Raisz LG, Rodan GA. San Diego: Academic Press Inc, 1996, 1019-35.
21. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. J Clin Invest 1997; 100: 2977-83.
22. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 33: 448-53.
23. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50-8.
24. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 2002; 17: 204-7.
25. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent. AMG 073 lowers parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-24.
26. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-54.
27. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum phosphorus, calcium x phosphorus product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
28. Llach F. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int 1999; 56(Suppl 73): S31-S7.
29. Juppner H, Brown EM, Kronenberg HM. Parathyroid hormone. In Metabolic bone diseases and disorders of mineral metabolism, 4th edn, ed. Favus MJ. Philadelphia: Lippincott Williams & Wilkins, 1999, 81-7.
30. Antonsen JE, Sherrard DJ, Andress DL. A calcimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid Comm Kidney Int 1998; 53: 223-7.
31. Naveh-Many T, Friedlaender MM, Mayer H, Silver J. Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1, 25-dihydroxyvitamin D. Endocrinology 1989; 125: 275-80.